Just when the outside world was in full swing about this contemporary artist's art exhibition, a series of sniper methods against Tiansheng Pharmaceutical had quietly begun.

First of all, the front page of "Hong Kong Island Daily" published a blockbuster news, openly questioning Tiansheng Pharmaceutical's financial fraud.

Then a number of media followed up on the news, and under the overwhelming negative publicity, Tiansheng Pharmaceutical's stock price fell sharply.

In just three days, Tiansheng Pharmaceutical, which had a market value of 102.5 billion at its peak, evaporated nearly 10 billion in market value, and its market value could be maintained at 90 billion.

Tiansheng Pharma launched an urgent research and angrily accused the unscrupulous media such as "Hong Kong Island Daily" for deliberately exaggerating the facts, causing huge losses to the company, and Tiansheng Pharma has sent lawyer's letters to six media including "Hong Kong Island Daily", saying that they will investigate the legal responsibility of these unscrupulous media.

Qin Huali himself is the big funder behind the "Hong Kong Island Daily", completely ignoring Tiansheng Pharmaceutical's warnings and continuing to publish various negative news about Tiansheng Pharmaceutical.

Within a week, Tiansheng Pharmaceutical's market value continued to shrink, from 100 billion to 86 billion.

Tiansheng Pharma tried every possible way to refute the rumors, and finally stopped the decline of the stock price, and the second wave of attacks against Tiansheng Pharma followed.

It was still the "Island Daily" that took the lead in disclosing the news that Tiansheng Pharma spent a huge amount of money on the research of a new drug for the treatment of cardiovascular and cerebrovascular diseases, which had serious side effects, and finally announced that the research failed.

The content of this report is very detailed, and all the details of the research process have been revealed.

The final failure of this drug directly led to a huge research investment of 5 billion over the years, which was lost.

For Tiansheng Pharmaceutical's huge investment in the research and development of original drugs, the outside world is very optimistic and supportive. Moreover, in the past few years, the research and development of this original drug has been very smooth, and good news will be disclosed from time to time, which has played a positive role in promoting the stock price.

Everyone knows that the investment in the original drug is a bottomless pit, and it is not so easy to get the research results.

However, Tiansheng Pharmaceutical's mistake is that it is too high-profile for R&D, and has repeatedly raised investors' expectations through this means, thereby pushing up the stock price. This has led to the fact that the majority of shareholders can only accept success and cannot accept the cruel reality of R&D failure.

Announcing the ultimate failure of the study now is a huge blow to confidence.

Tiansheng Pharma's stock price has increased with the help of new drug research and development, and how much it has fallen now. Even under the deliberate impetus of the sniper team, the decline was greater and faster.

On the day the news was disclosed, Tiansheng Pharmaceutical's stock price fell sharply again.

This time, the negative news is real, and all kinds of real hammers continue to be disclosed, and Tiansheng Pharmaceutical's dry explanation and the explanation of continuing to increase the investment in original drugs are not helpful at all.

Tiansheng Pharmaceutical's share price continued to fall after the sharp fall, and in just 5 days, the original market value of 100 billion yuan shrank to 65 billion.

The management of Tiansheng Pharma can be said to be exhausted during this period of time, and tried every possible way, but still could not stop the sinister situation of the continuous decline in the stock price.

Just when the majority of shareholders thought that Tiansheng Pharmaceutical's stock price had bottomed out and was about to rebound, the real fatal blow suddenly came.

Yuanhang Pharmaceutical Co., Ltd. and KPG Pharmaceutical Research Institute jointly held a press conference and invited major media reporters to attend in a high-profile manner.

Yuanhang Pharmaceutical is not well-known, but it is just a medium-sized pharmaceutical company in Nanyang, but KPG Pharmaceutical Research Institute is a famous name, and has launched a number of best-selling drugs in a row in recent years.

Such a high-profile press conference, the content is really exciting enough.

The two best-selling new drugs for the treatment of cardiovascular and cerebrovascular diseases of the KPG Pharmaceutical Research Institute were won by Yuanhang Pharmaceutical in one fell swoop for the exclusive patent authorization in the next 15 years.

If the news is limited to this, it is not sensational enough, but if you add that the authorized patents of these two drugs are snatched from Tiansheng Pharmaceutical, the influence of this news is greater.

The response of the Island Daily was the quickest, and a detailed analysis of the piece of information was published on the official website just after the press conference ended.

Through the disclosure of "Hong Kong Island Daily", shareholders learned that the sales performance of Tiansheng Pharmaceutical in recent years has increased year by year, and the main contributors are these two new drugs from KPG.

The profits of these two new drugs accounted for nearly half of the annual profits, which was originally good news to increase the stock price, but now Tiansheng Pharmaceutical has not won the follow-up patent licensing, and the good news has suddenly become a life-threatening charm.

The loss of the patent licensing of these two drugs means that Tiansheng Pharma will lose nearly half of its profits every year, which is simply unbearable.

The blow was fatal!

The disclosure of this news is equivalent to digging out the taproot of the big tree of Tiansheng Pharmaceutical, and if you are not careful, Tiansheng Pharmaceutical is in danger of collapsing.

Fell...... Fell...... Or down!

Tiansheng Pharmaceutical's share price began to fall off a cliff, and in just three days, it fell below the issue price.

A week later, Tiansheng Pharmaceutical's market value shrank to 45 billion.

At this point, the stock price has bottomed out, and there is basically no room for shrinkage.

Tiansheng Pharmaceutical is not an asset-light Internet stock, and its market value of 45 billion is already undervalued, and it is impossible to continue to fall.

Tiansheng Pharmaceutical's outstanding shares account for 40% of the total share capital, and Qin Huali's acquisition team, together with Swire Pacific, has acquired a total of 30% of the shares from the market, while the acquisition capital is only 16 billion yuan.

It happened too suddenly, Zeng Zhaoquan was very vigilant about the two major shareholders who suddenly appeared, and wanted to increase his shareholdings, but unfortunately he couldn't get the funds for a while.

When he mortgaged his shares and successfully got the loan, there were not many outstanding shares in the market, and Zeng Zhaoquan only increased his stake from 35% to 40%.

For the acquisition of Tiansheng Pharma this time, the reason why Xiao Yao entrusted Qin Huali to lead it, rather than Swire Investment, was to use Qin Huali's personal connections.

If it is only an operation in the financial market, Swire Investment is professional enough, but when it comes to over-the-counter acquisitions, Qin Huali's personal energy is very crucial.

Tiansheng Pharmaceutical's equity is relatively dispersed, Zeng Zhaoquan is the largest shareholder, accounting for 35% of the total share capital, 40% of the outstanding shares in the market, and the remaining 25% is in the hands of 7 shareholders. The largest one owns 8.7 percent of the shares, and the least one owns 1.2 percent.

The negotiation with these 7 shareholders fully demonstrated Qin Huali's strong energy, and he invested a total of 13 billion yuan at an average premium of 15% to successfully win the 25% shares.

So far, Qin Huali has won 55% of the shares, and the total acquisition capital invested is 29 billion yuan.